Last reviewed · How we verify

NCT06094192

Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation

Recruiting now NA Last updated 19 September 2025
What this trial tests

NA trial testing High definition transcranial electrical current stimulation in Alzheimer Disease in 204 participants. Currently enrolling.

Timeline
20 December 2023
Primary endpoint
31 May 2028
31 May 2028

Quick facts

Lead sponsorBoston University Charles River Campus
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposebasic science
Enrollment204
Start date20 December 2023
Primary completion31 May 2028
Estimated completion31 May 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Boston University Charles River Campus

Who can join

Adults 50 to 100, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will evaluate the theory that Alzheimer's disease-related memory impairment derives from the inefficient orchestration of rhythmic activity at the level of large-scale cortical networks. The results as expected to elucidate AD-related pathophysiology and set groundwork for the development of drug-free interventions for improving memory in AD and related dementias.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of High definition transcranial electrical current stimulation

Trials testing the same drug.

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

Other Boston University Charles River Campus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06094192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing